The clock is quickly ticking down towards Hemispherx Biopharma's (HEB) Food and Drug Administration (FDA) December 20th meeting with the Arthritis Advisory Committee (AAC) to discuss Ampligen's New Drug Application (NDA) for Chronic Fatigue Syndrome (CFS). As previously announced, the Prescription Drug User Fee Act (PDUFA) review goal for Ampligen is February 2nd, 2013.
Hemispherx Biopharma: A Voice Of Reason Amid The Din - Seeking Alpha
But, another story on Yahoo News shows that the company has been selling shares
behind the scenes. Check it out.
Please register to participate in our discussions with 2 million other members - it's free and quick! Some forums can only be seen by registered members. After you create your account, you'll be able to customize options and access all our 15,000 new posts/day with fewer ads.
